A B S T R A C T The release of human platelet constituents by the etiologic agent of gout, the monosodium urate crystal, is described here. Both phases were inhibited by iodoacetate plus dinitrophenol, suggesting an energy requirement. In ultrastructural studies, lysis of washed platelets which appeared to contain crystals was seen. Urate crystals were also shown to induce serotonin release and platelet lysis in citrated platelet-rich plasma.
INTRODUCTION
Recent studies have suggested a role for platelets in inflammation by release ofmediators such as vasoactive amines (1-3), chemotactic activity-generating factors (4) , permeability-enhancing factors (5, 6) , bactericidal proteins (7) , and prostaglandin intermediates (8) during platelet activation. Monosodium urate crystals are particles deposited in diverse tissues in gouty individuals (9) where they might then come in contact with platelets and are the initiators of inflammation (10, 11) This is publication no. 1246 from the Department of Immunopathology, Scripps Clinic and Research Foundation, La Jolla, Calif. 92037. This work was presented in part at the American Federation for Clinical Research Midwest Meetings, Chicago, Ill., November 1974 .
Received for publication 28 June 1976 and in revised form 30 June 1977. in this disease. Various other particulates stimulate platelets in vitro (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . This led us to ask, Does the activation of platelets play a role in gouty inflammation? As a first step in answering this question, we have studied the interaction between the particle found in human gout, i.e., microcrystalline monosodium urate, and human platelets.
In this report we demonstrate urate crystal-induced platelet activation as assessed by serotonin release in citrated platelet-rich plasma and serotonin, ATP and ADP release, shape change, and lysis in suspensions of washed platelets.
METHODS Chemicals
The following were obtained from Sigma Chemical Co., St 
Thin-layer chromatography
This was performed with precoated silica gel thin-layer chromatography plates (EM Laboratories, Inc., Elmsford, N. Y.) in an ascending ethyl acetate:isopropanol:NH40H (60:35:5) system which resolved a serotonin standard from 5-hydroxytryptophol and 5-hydroxy-indole acetic acid standards. The radioactivity migrating with 100 ,g of carrier serotonin creatinine sulfiate was determined as was the radioactivity on the remainder of the plate. Results were expressed as percenit of total radioactivity migrating with the carrier serotonin.
Hagenman2 factor activation A crude estimiiate of Hageman factor activationi was obtainied by a standard partial thromnboplastin time assay (29) using 2%o Celite filter cel suspension (Johns-Manville, Denver, Colo.) rather than kaolin as a positive substance control. One-tenth of the material to be tested, or of Celite, was incubated with pooled normal plasma at 37°C for 4 min, 0. Urate crystals induced serotonin release in suspensions of washed platelets, whereas addition of supersaturated urate solution to a final concentration of 6 mg/100 ml failed to induce release, indicating that the physical state of the crystals was important. That released radioactivity represented serotonin was next verified.
Identity of released serotonin. In this experiment 0.8 mg/ml urate crystals induced release of 76+5.5% of radioactivity from [14C]serotonin-labeled platelets at 10 min. In thin-layer chromatographic studies, 86.4 ±2.1% (SE) ofthe released radioactivity was associated with the carrier serotonin standard. 85.4±2% of radioactivity recovered from sonicated labeled platelets and 90±1.5% of radioactivity released in the presence of 5 NIH Units/ml of crude bovine thrombin (Park, Davis & Co., Detroit, Mich.) (released 95±1.2% of platelet radioactivity) migrated with a serotonin standard. modify platelet response to surfaces (16) and are known to affect the surface properties of urate crystals, these experiments were done in TBS, pH 7.4, but similar data was obtained using albumin density gradient-prepared cells. The dense body constituent (31), serotonin, was released within the first 10 min of incubation; in contrast, /8-glucuronidase and cytoplasmic LDH were not detectably released during the first 10 min. ADP and ATP were released with the same time course FIGURE 2 Effect of metabolic inhibitors on urate crystal-induced washed platelet release reaction. Washed platelet suspensions were incubated at 37°C for 10 min with either buffer (left panels) or a combination of 0.5 mM 2,4-DNP and 0.1 mM iodoacetate (right panels). Percent release of platelet constituents 10 (lower panels) and 30 (upper panels) min after addition of 1 mg/ml urate crystals was determined. 5HT = serotonin, 3- Effect of metabolic inhibitors. A combination of 0.1 mM iodoacetate and 0.5 mM 2,4-DNP, which blocks both anaerobic glycolysis and oxidative phosphorylation, inhibited both early and late components of serotonin release (Fig. 2) . LDH and 18-glucuronidase loss were inhibited as well. This suggests that urate crystal-induced lysis is initially an active process.
Effect of white cell contamination. PMNs alone in concentrations many times that present in our platelet suspensions released only a small fraction of the enzyme activity released by platelets. For example, incubation of a platelet suspension containing 8. (Figs. 4 and 5) were Morphologic studies. The ablumin density gradi-seen in platelets incubated with urate crystals. The ent-prepared platelets (Fig. 3) were discoid, had intact crystal-treated samples showed bizarre shape changes membranes, contained storage granules, and had an and degranulation. In some cells with intact cell memUrate Crystal-Induced Platelet Release 1003
:p wEt FIGURE 5 Effect ofurate crystals on washed platelets. Treatment as described in legend to Fig. 4 . Arrows: crystal artifact free in cytoplasm of lysed platelet. Arrowheads: platelet with intact cell membrane containing only one questionable crystal artifact. x47,000.
branes, crystal artifacts (Fig. 4) were noted inside membrane-lined compartments. In other cells (Figs. 4 and 5) there were huge gaps in the cell membrane and loss of cytoplasmic structure indicating cell lysis; in these cells, crystal artifacts (Figs. 4 and 5) were noted free in the cytoplasm. Platelets prepared in TBS also showed apparent crystal uptake and cell lysis, but the presence of shape change in buffer controls made assessment of this parameter impossible in TBS.
Studies in platelet-rich plasma
Because urate crystals activated washed platelets, their effects in platelet-rich plasma were examined.
Effect of crystals in PRP. Monosodium urate crystals induced release of serotonin in citrated PRP with peak release occurring at 10 min incubation. This property was shown by unheated crystals as well as by crystals heated to 200°C for 2 h. Different PRP preparations released from 5 to 45% of serotonin in response to 0.8 mg/ml urate crystals, indicating variability in individual donors' platelet response to urate crystals in PRP.
Evidence that crystal-induced serotonin release in PRP is active. Since urate crystals are themselves membranolytic (32) , it is possible that the serotonin release was due to a passive loss in platelet membrane integrity. As shown in Fig. 6 , urate crystalinduced serotonin release in PRP was inhibitable by iodoacetate plus dinitrophenol or by EDTA, suggesting that it is an active process. Proteases generated subsequent to Hageman factor activation in plasma (33) , such as thrombin, plasmin (34) , and Factor Xa (35) , have been reported to induce the platelet release reaction. Since crystals activate Hageman factor (36) , the possibility that such interaction was the cause of crystal-induced serotonin release in PRP was explored.
Effect (38) reported that 5 times the dose of thrombin inducing maximal serotonin release (81.3%) from human platelets was associated with loss of only 1.6% of LDH. Similar data were obtained in our preparations. Thus, the lytic activity of the urate crystal for human platelets is greater than that of thrombin. Henson (39) has demonstrated that neutrophils enhance rabbit platelet serotonin release induced by aggregated IgG or immune complexes, but that this phenomenon does not occur with human platelets and neutrophils (40) . In our studies, increasing neutrophil contamination of up to 106 per ml did not alter the release reaction induced by urate crystals.
In vivo platelets are suspended in plasma. Thus, the demonstration that urate crystals induce active serotonin release in PRP adds weight to the possibility of crystal-induced platelet activation in vivo. The failure of ellagic acid, an activator of Hageman factor (37) , to release serotonin in PRP shows that Hageman factor activation per se is not sufficient to account for urate crystal-induced serotonin release in PRP.
In PRP approximately 10 times as many urate crystals were required to initiate platelet lysis as in suspensions of washed platelets. Thus, platelets may be added to red cells (32) Urate crystal deposition is not limited to articular structures in gouty patients; for example, crystals occur in subcutaneous tophi and heart valves (41) and have been reported in blood vessels (42) . The role of platelet activation in intra-and extra-articular gouty inflammation would now seem to require further study. Similarly, urate crystals in blood vessels might lead to local platelet activation with endothelial damage (43) and possible mural thrombosis. Such a sequence of events could play a role in the increased platelet turnover (44) and risk of vascular disease in gouty patients (45) .
